The Innovation Department is an accredited TECNIO agent in the category of Developers and Technology Enablers.
The TECNIO seal is awarded by the Government of Catalonia, through ACCIÓ, and identifies key technology providers and facilitators in Catalonia. This seal supports the most qualified agents involved in technology transfer; allows companies to access advanced R&D to develop new products and services; increases the scope of technology projects by finding the most suitable technology partners & suppliers; and helps raise competitiveness and technological innovation capacities.
VALUNI 2016 aims to promote the commercialization of projects and technologies by supporting key activities that facilitate the licensing of patents and/or creation of technology-based companies. Two projects promoted by the Innovation Department were awarded in 2017: “Colostage Technology” and “Gate2Brain – transport de molècules al cervell”.
Gínjol is a new patent fund set up by CERCA, an organization belonging to the Government of Catalonia that supervises, supports and facilitates the activities of research centres in Catalonia. IRB Barcelona received funding for the two projects submitted by Innovation Department in the first call for application launched at the end of 2016. Two patents at IRB Barcelona were awarded in the first Gínjol call: “Oncoselective mechanism for gene or viral therapy”, and “A novel and promising new target against Alzheimer’s disease".
The Premi Pioner seeks to recognize researchers at CERCA centres who, in the last 18 months, have defended a doctoral thesis that has a clear orientation towards launching or strengthening a technology or product of industrial or commercial interest or that can make a significant contribution to the development of public policies. In 2015, Benjamí Oller, former PhD student in Prof. Ernest Giralt’s lab, was awarded this prize for his thesis, entitled “From bee venom to blood-brain barrier shuttles. Development of minimized apamin derivatives for brain delivery of antibodies and other cargoes”.
The type of high-risk/high-gain research at the frontiers of knowledge that the ERC promotes often generates unexpected or new opportunities for commercial and societal applications. The ERC is committed to ensure the full exploitation of the excellent, useful ideas it funds. The Proof of Concept funding helps ERC grant-holders bridge the gap between their research and the earliest stage of a marketable innovation.
VALUNI 2015 aims to encourage action plans of marketing units to promote technology commercialization via the licensing of patents and/or creation of technology-based companies. Furthermore, it seeks to strengthen technology projects and marketing activities in order to ensure effective technology transfer to the productive sector. The Innovation Department was granted this funding for the project INNOVal 2015.
BiomedTec is an IRB Barcelona internal programme supported by the Obra Social la Caixa and devoted to validate early-stage technologies from all disciplines. The development of the BiomedTec programme will foster the transfer of scientific results to the market, thus improving the quality of life of patients with cancer.
The first call was in 2012 and devoted to cancer. Due to the success of this first call, applications were broadened to all therapeutic areas. From the second call onwards it was officially denominated BiomedTec.
The Innovation Department is working to assure the continuation of the programme for the forecoming years.
Launched by the Botín Foundation, the “Mind the Gap” Technology Transfer Investment Programme supports the development of products and services that arise from lab bench results. IRB Barcelona has been awarded two “Mind the Gap” projects: “COLOSTAGE”, which is led by Drs. Eduard Batlle and Elena Sancho and aims to develop a diagnostic test for patients at risk of metastasis, and “NOSTRUM DRUG DISCOVERY”, a drug design platform headed by Dr. Modesto Orozco. The IRB Barcelona projects, two of the three chosen by the Foundation in 2012, will receive 500,000 euros each, as well as management, coordination and consulting support for two years.
President of the Foundation of the National Institutes of Health and President of the IRB Barcelona Business Advisory Board
«Sometimes the best way to make research useful for society is to publish and bring new knowledge into public domain. In addition, we need to patend discoveries to guarantee their commercialization and provide incentives for pharmaceutical companies to develop drugs.»
Mª Teresa Tarragó
Alumni - Research Associate
«If you have good knowledge of science and the skills to organise and lead a team, you can do other exciting and interesting things besides research.»
Co-founder of Iproteos.
«One of my goals when choosing IRB Barcelona was also to gain experience in tech transfer. I have ideas. And I want to learn how to convert them into a business.»
Group: Gene Translation Laboratory
«One of the parameters for where I wanted to work was how easy it would be to start a spinoff, Barcelona—and the IRB— seemed to be a great place to go.»
Founder of Omnia Molecular
Group: Colorectal Cancer Laboratory
«Our project, Colostage, aims to prevent patients who aren't at risk of developing metastasis from undergoing chemotherapy treatments which can be costly, unnecessary, and very aggressive. Our test will really help doctors chose the best choice of treatment for their patients. At the same time it will lead to substantial savings for the healthcare systems.»
More about this here.
«Our Friedrich's Ataxia project is maginificent because it has come about from the patients. It reminds us that answers are provided by basic research, the cornerstone of all future applications.»
More on this news here.
«The innovation course has been one of the best experiences during my PhD at IRB Barcelona. It gave me insights into business development in the biotechnology sector, encouraging me to do science in a way that I found particularly attractive.»
«Inbiomotion is an example of how academic basic research can provide grounds to address an unmet medical need, making a step forward in the clinical standard of care using personalized medicine to prevent cancer metastasis.»
Founder of Inbiomotion